System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Michio Shimabukuro is an expert in Cardiology at Fukushima Medical University (Japan). As of October 2026, ScienceLeadR ranks Michio Shimabukuro in the top 1% of experts worldwide for Glucose Metabolism Disorders and Diabetes Mellitus, and in the top 1% of experts in Japan for Body Weight. Michio Shimabukuro has authored 385 publications, the most recent in 2026, and is an investigator in 4 clinical trials, 2 of them ongoing. SLR score: 1,135 (community average: 125). How the SLR is computed.

LeadR Profile

Michio Shimabukuro Fukushima Medical University Japan
1 135 ScienceLeadR Reputation 1135

Unlock

Register Login
Network Map

Cardiology

Subspecialties: Endocrinology - Public Health - Hematology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1994 - 2026
Source: PubMed

Fukushima Medical University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 385

Citations

Citations: 16 225 1st author: 42 Last author: 53 Unique author: 19

Main journals

J Atheroscler Thromb 22
Sci Rep 20
Eur Heart J 18
Cardiovasc Diabetol 17
Circ J 16

Best Journals

Eur Heart J 2
JAMA 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Associations Between Dietary Habits and Sleep Duration in Japanese Children: The Fukushima Health Management Survey.
PMID 42836436 — sleep, feeding behavior, aged, adolescent, pediatrics, child		Pediatr Int20260
Seasonal Variation in Metabolic Syndrome and Its Association With Meteorological Factors: A Large Population-Based Study in Fukushima, 2012-2022.
PMID 42426376 — public health, sex, sunlight, metabolic syndrome, temperature		J Epidemiol Glob Health20260
Data-Driven Diabetes Clustering in East Asians: Pathological Heterogeneity and Personalized Medicine.
PMID 42605192 — diabetes mellitus, endocrinology, genes, insulin, cluster analysis, precision medicine, therapeutics		J Clin Endocrinol Metab20260
Randomized Trial of Finerenone on Urinary Albumin-to-Creatinine Ratio in Type 2 Diabetes Mellitus and CKD.
PMID 42180819 — diabetes mellitus, creatinine, diabetes mellitus, type 2		Kidney Int Rep20260
Resting Heart Rate and Incident CKD Among Individuals With CKD Risk Factors.
PMID 42163020 — kidney diseases, confidence intervals, heart rate, heart, cohort studies, risk factors		Nephrology (Carlton)20260

Clinical Studies 4

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 4 4

By status:

Active not recruiting 2
Completed 2

By type:

Interventional 4

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 1
multicentric5to9 0
multicentricup10 0

Main Topics

Cohort/Consortium Investigators 3

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE STAR)
NCT05887817 — diabetes mellitus, kidney diseases, kidney, biomarkers, renal insufficiency, vascular stiffness, renal insufficiency, chronic, diabetes mellitus, type 2		Phase 4Active not recruiting2023
Program of Angiotensin Neprilysin Inhibition in Admitted Patients With Worsening Heart Failure (PREMIER)
NCT05164653 — enzyme inhibitors, angiotensin ii, valsartan, administration, oral, receptors, angiotensin, angiotensin-converting enzyme inhibitors, safety, hospitalization, heart failure, pharmaceutical preparations, heart, peptidyl-dipeptidase a, drug combinations, tablets, neprilysin, angiotensins, angiotensin receptor antagonists, enzymes, therapeutics		Phase 4Active not recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS